Literature DB >> 28570904

Dual burden of chronic physical diseases and anxiety/mood disorders among São Paulo Megacity Mental Health Survey Sample, Brazil.

Melanie S Askari1, Laura Helena Andrade2, Alexandre Chiavegatto Filho3, Camila Magalhães Silveira2, Erica Siu2, Yuan-Pang Wang2, Maria Carmen Viana4, Silvia S Martins5.   

Abstract

BACKGROUND: We assessed comorbid associations of 12-month DSM-IV mood/any anxiety disorders with chronic physical conditions within the São Paulo (SP) Megacity Mental Health cross-sectional survey of 5037 participants and explored whether strength of comorbid associations were modified when controlling for demographics.
METHODS: Chi-square tests and logistic regressions were used to examine comorbid associations of DSM-IV mood/anxiety disorders as measured by the WHO Composite International Diagnostic Interview (CIDI 3.0), and self-reported chronic physical conditions among adults from the SP Megacity Mental Health Survey.
RESULTS: Among those with any mood or anxiety disorder, chronic pain disorder was the most common physical condition (48.9% and 44.9%, respectively). Significant unadjusted odds ratios (OR) of comorbidity were found between diagnosis of two or more physical conditions and any mood disorders (3.08, 95% CI: 2.27-4.17), and any anxiety disorders (2.49, 95% CI: 1.95-3.17). Comorbidities remained significant when stratified by gender and controlling for marital status, household income, and education (latter two only included within anxiety models). LIMITATIONS: These results cannot be generalized to other cities or rural populations. Homeless and institutionalized populations were not surveyed. Due to cross-sectional study design, the direction of association between chronic disease/chronic disease risk factors and mood disorders is unclear.
CONCLUSIONS: Dual burden of chronic physical conditions and mood/anxiety disorders is a notable problem among the São Paulo Megacity Survey population, with enhanced comorbidity experienced by community members with multiple physical conditions. Clinicians should consider these findings in understanding healthcare delivery for individuals suffering from both psychiatric disorders and chronic physical conditions.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety disorder; Chronic condition; Comorbidity; Mood disorder

Mesh:

Year:  2017        PMID: 28570904     DOI: 10.1016/j.jad.2017.05.027

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  Emotional problems and health-related quality of life: population-based study.

Authors:  Camila Stéfani Estancial Fernandes; Margareth Guimarães Lima; Marilisa Berti de Azevedo Barros
Journal:  Qual Life Res       Date:  2019-06-19       Impact factor: 4.147

2.  The impact of comorbid spinal pain in depression on work participation and clinical remission following brief or short psychotherapy. Secondary analysis of a randomized controlled trial with two-year follow-up.

Authors:  Marjon E A Wormgoor; Aage Indahl; Jens Egeland
Journal:  PLoS One       Date:  2022-08-22       Impact factor: 3.752

3.  Assessing the impact of urban environment and green infrastructure on mental health: results from the São Paulo Megacity Mental Health Survey.

Authors:  Tiana C L Moreira; Jefferson L Polize; Marceli Brito; Demostenes F da Silva Filho; Alexandre D P Chiavegato Filho; Maria Carmem Viana; Laura Helena Andrade; Thais Mauad
Journal:  J Expo Sci Environ Epidemiol       Date:  2021-06-11       Impact factor: 5.563

4.  Comparative Effect of Collaborative Care, Pain Medication, and Duloxetine in the Treatment of Major Depressive Disorder and Comorbid (Sub)Chronic Pain: Results of an Exploratory Randomized, Placebo-Controlled, Multicenter Trial (CC:PAINDIP).

Authors:  Eric W de Heer; Jack Dekker; Aartjan T F Beekman; Harm W J van Marwijk; Tjalling J Holwerda; Pierre M Bet; Joost Roth; Lotte Timmerman; Christina M van der Feltz-Cornelis
Journal:  Front Psychiatry       Date:  2018-04-05       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.